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Abstract: The genetic code is universal, but recombinant protein expression in heterologous
systems is often hampered by divergent codon usage. Here, we demonstrate that reprogramming
by standardized multi-parameter gene optimization software and de novo gene synthesis is a
suitable general strategy to improve heterologous protein expression. This study compares
expression levels of 94 full-length human wt and sequence-optimized genes coding for
pharmaceutically important proteins such as kinases and membrane proteins in E. coli.
Fluorescence-based quantification revealed increased protein yields for 70% of in vivo expressed
optimized genes compared to the wt DNA sequences and also resulted in increased amounts of
protein that can be purified. The improvement in transgene expression correlated with higher
mRNA levels in our analyzed examples. In all cases tested, expression levels using wt genes in
tRNA-supplemented bacterial strains were outperformed by optimized genes expressed in
non-supplemented host cells.
Keywords: synthetic genes; gene optimization; heterologous protein expression; fluorescence-
based quantification; codon usage; recombinant proteins
Introduction
Escherichia coli (E. coli) is the most commonly used
system for production of recombinant human pro-
teins. Despite its known limitation in protein folding
and its inability to perform certain post-translational
modifications, proteins expressed in and purified
from E. coli are widely used as research tools, for
example, in proteomics for various functional and
structural analyses or as biopharmaceuticals.
1,2 Rea-
sons for choosing E. coli as an expression host are
its fast growth and its well understood genetics
which offers an unmatched toolbox for genetic engi-
neering. However, high-level and reliable transgene
Abbreviations: 6xHis tag, hexahistidine tag; IMAC, immobilized
metal affinity chromatography; wt, wild type
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systems is often hampered by the presence of non-
frequently used codons within the gene-coding
region. There is a strong correlation between the
availability of tRNAs and the frequency their respec-
tive codon is used by the expressing host.
3 Codons
not favoured by E. coli are for example, AGG and
AGA which both code for Arginine and frequently
occur in human genes. A strategy to overcome
expression limitations caused by non-preferred co-
dons is to co-express certain tRNAs. Although co-
expression of selected tRNAs can overcome expres-
sion problems to some extend due to the presence of
extremely rare codons, it has been reported that
best and most consistent expression of a malaria
protein has been achieved only by consequently
adapting the entire gene to most frequently used E.
coli codons.
4 In addition to codon choice and tRNA
availability, other sequence-based factors influence
expression yields, for example, the presence of an 8
base pair stem loop structure near the Shine-Dal-
garno ribosomal entry site
5 and the AU-content of
the mRNA.
6,7 The presence of intragenic sequences
mimicking E. coli ribosomal entry sites, as found in
many mammalian genes, may lead to truncated
products during heterologous expression
8 and should
be avoided. Therefore, sequence optimization has to
be balanced between introducing frequently used co-
dons and avoiding mRNA secondary structures,
extreme GC-content and DNA motifs such as inter-
nal ribosomal entry sites for which usually elabo-
rated software is necessary.
9 Only true multi-param-
eter algorithms allowing weighted and paralleled
optimization of local sequence features without limi-
tations regarding the analyzed sequence space will
allow consistent and reproducible results.
9,10
Rational gene optimization in conjunction with
de novo gene synthesis has been shown to enhance
transgene expression in various host cells and in
numerous examples.
11–16 However, these studies
were limited to few and randomly selected proteins
or a single protein family (short chain dehydroge-
nases/reductases)
11 and therefore do not provide sys-
tematic insight into the potential of using codon-
optimized sequences in heterologous transgene
expression. Accordingly, it is still unclear whether
the use of rationally designed synthetic genes can
generate expression templates that are generally
superior to cloned cDNA’s in terms of (i) availability,
(ii) quality as well as (iii) reliability and (iv) level of
expression, and all this over a representative range
of protein classes. To address these issues, genes
from five important functional groups of the human
proteome have been selected for this study, compris-
ing (i) RNA polymerases and ribosomal subunits, (ii)
polypeptides involved in transcription, (iii) protein
kinases, (iv) GPCR’s and other membrane proteins,
as well as (v) cytokines and chemokines. Altogether,
100 full-length human reading frames have been
optimized for expression in E. coli for subsequent
comparison with the corresponding wt genes. The
optimized reading frames were synthesized de novo
and the respective wt cDNAs were retrieved from
public clone selections where available or likewise
synthesized de novo. To facilitate the comparative
analysis, all genes were placed under the transcrip-
tional control of the T7 promoter and fused to the 30
end of a 50-[6x Histidine] tag. All selected genes
encoded for the same amino acid sequence as it can
be retrieved from the NCBI EntrezGene database.
This is the largest comparative study conducted so
far on expression of wt and optimized genes analyz-
ing different sets of protein classes with regard to
enhanced expression yield and underlying mecha-
nism for this enhancement.
Results
RNA and codon optimization strategy
The degeneration of the genetic code and the possi-
bility to use synonymous codons provide a powerful
tool to circumvent limitations of recombinant expres-
sion. However, the sequence space encoding even
small peptides is so vast that efficient software algo-
rithms are necessary to identify the putative best
sequence encoding the very same native protein as
the wt sequence. Here, we used a sliding combina-
tion window (7 codons) in which any possible
sequence encoding the same peptide as the respec-
tive wt sequence is generated.
17 Each sequence was
analyzed regarding the following parameters: codon
quality, GC-content, DNA motifs like ribosomal
entry sites and probability to form stable mRNA sec-
ondary structures. By a weighted scoring and pen-
alty system the ideal sequence was automatically
identified within the given window. By sliding this
window from the 50 end towards the 30 end, the opti-
mized full-length sequence was generated without
limiting the analyzed sequence space by random
generators as Monte Carlo approaches would do.
Multi-gene study: Gene selection and synthesis
In the multi-gene study presented here, in vivo
expression levels of wt and sequence-optimized
human genes were analyzed in E. coli. 100 proteins
were chosen comprising a peer group of candidates
from five important protein classes within the
human proteome: transcription factors, RNA poly-
merases and ribosomal subunits, protein kinases,
membrane proteins and cytokines as secreted pro-
teins. Our study included 45 proteins of more than
50 kDa whereas eleven candidates covered a mass of
100 to 264 kDa. Furthermore, membrane proteins
which are difficult to express represent the second
Maertens et al. PROTEIN SCIENCE VOL 19:1312—1326 1313largest category within this study (28 members). For
reasons of comparability, we expressed every wt and
sequence-optimized construct under standardized
conditions only, without pursuing systematic domain
or tag screenings or any other optimization efforts.
All analyzed genes are summarized in Table I and
all sequences are listed in Supporting Information
Table I. Due to unavailability at public clone selec-
tions (e.g., RZPD, geneservice), nonsilent mutations
and difficulties with cloning, only 34 out of 100 wt
clones were successfully cloned by performing PCR
on cDNAs as a template (Table I). Thus, 66 of 100
wt genes also needed to be synthesized de novo. Syn-
thesis of 6 wt genes (Gene Bank Acc. No’s
NM_002011, NM_002576, NM_002577, NM_005760,
NM_022451 and NM_014233) was impossible, since
in these cases PCR and/or oligonucleotide assembly
failed repeatedly due to unfavorable sequence com-
position and therefore had to be excluded from the
side-by-side expression comparison study. In con-
trast, 99 optimized genes encoding the selected
panel of proteins could be synthesized successfully,
as we could make use of the relative freedom of
sequence design. If annotated in the NCBI database
as cleavable, sequences representing signal peptides
were omitted for expression of mature human pro-
teins in E. coli.
Workflow of multigene study
An expression vector (pQE-T7) with combined fea-
tures for cell-free and in vivo expression was devel-
oped. To facilitate detection and purification, the
vector fuses a N-terminal hexahistidine (6xHis) tag
to the recombinant protein as described in Figure 1.
Tight regulation with little or no basal expression in
vivo was shown for the pQE-T7 vector equipped with
a T7 promoter (Supporting Information Fig. 1). In
preparation of our in vivo study, we analyzed the
impact of using either IPTG or an autoinduction me-
dium
20 on the expression yields of six selected pro-
teins representing the various protein classes. In
addition to simplified handling, the autoinduction
medium consistently resulted in higher cell densities
and expression levels from equal culture volume
compared to conventional IPTG induction (Support-
ing Information Fig. 2). Furthermore, cultures
expressing sequence-optimized constructs showed a
higher cell density per volume in both induction sys-
tems [Autoinduction OD600 nm 5.6 (wt) versus 8.1
(opt) on average; IPTG OD600 nm 2.1 (wt) versus 2.9
(opt) on average, respectively]. This suggests a more
efficient translation of optimized heterologous tran-
scripts probably by allowing an increased total rate
of protein synthesis which results in accelerated cell
growth.
Each wt-cDNA and its sequence-optimized coun-
terpart were expressed in E. coli BL21(DE3). A dye
(Chromeo P503), which only becomes fluorescent
once it is conjugated to an amino group of a protein,
was added to each lysate in excess.
21 The absolute
fluorescence was then measured with a fluorescent
imaging system by scanning with decreasing inten-
sity until no saturation was visible. The protein
band of interest was drawn on to determine the
absolute expression (Workflow Fig. 1). For quantita-
tive comparison, the mean fluorescence value from
three independent expressions was calculated and
the expression level of optimized genes was divided
by the wt value. A ratio value >1 implies a higher
expression level for the optimized sequence, a ratio
value <1 a higher level for the wt sequence, respec-
tively (Table I, column opt/wt). The most important
findings from the analysis of Table I are summarized
in Table II.
Impact of gene optimization on reliability and
levels of transgene expression
Altogether, 54 out of 94 optimized expression con-
structs (57.5%) performed equal or better than their
wt counterparts (Table I). On the contrary, 19 opti-
mized constructs (20.2%) performed slightly weaker
and further 21 full-length constructs, neither wt nor
optimized showed any expression at all under stand-
ardized conditions. Within the group of proteins that
could be expressed in E. coli cells (73 out of 94),
gene optimization resulted in significantly higher
expression levels in 51 cases (70%; Table II). Expres-
sion levels of optimized human genes in E. coli were
elevated up to 50-fold compared to wt sequences. In
nine cases, we observed protein expression in vivo
exclusively using optimized sequences, whereas the
wt cDNAs failed to support any transgene expres-
sion. Here, the increase of expression level could not
be quantified by our method and was estimated indi-
vidually (Supporting Information Fig. 3). The mean
of expression enhancement (ratio total expression,
opt/wt) using sequence-optimized genes was 3.5-fold
for expressible genes and the median 1.29 (Table II).
The overall chance to express one of the 100 proteins
raised from 69 to 78% using sequence-optimized con-
structs under standardized expression conditions
[Supporting Information Fig. 4(A)]. To focus on the
individual protein classes, especially cytokines bene-
fit from gene optimization in terms of enhanced
expression level whereas the effect is less pro-
nounced in the class of transcription factors (median
values of 1.56 and 1.17, respectively; Supporting In-
formation Fig. 4(A). On the other hand, however,
one transcription factor (TFIIA) was one of the pro-
teins in the study that benefitted most from optimi-
zation (50-fold) and this contributed to the resulting
average increase of expression for transcription fac-
tors (mean value of 5.11). Gene optimzation
increased the success rate for protein expression
most significantly in the groups of cytokines, tran-
scription factors and membrane proteins [100%
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a
b
l
e
I
.
S
i
d
e
-
b
y
-
S
i
d
e
C
o
m
p
a
r
i
s
o
n
o
f
1
0
0
w
t
a
n
d
S
e
q
u
e
n
c
e
-
O
p
t
i
m
i
z
e
d
H
u
m
a
n
G
e
n
e
s
R
e
f
_
s
e
q
.
N
a
m
e
P
r
o
t
e
i
n
s
i
z
e
(
k
D
a
)
W
i
l
d
-
t
y
p
e
c
o
n
s
t
r
u
c
t
c
o
r
r
e
c
t
a
n
d
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
O
p
t
i
m
i
z
e
d
c
o
n
s
t
r
u
c
t
a
v
a
i
l
a
b
l
e
u
p
o
n
d
e
n
o
v
o
s
y
n
t
h
e
s
i
s
r
a
t
i
o
t
o
t
a
l
e
x
p
r
e
s
s
i
o
n
(
o
p
t
/
w
t
)
K
i
n
a
s
e
s
N
M
_
0
0
2
6
4
8
P
i
m
-
1
o
n
c
o
g
e
n
e
(
P
I
M
1
)
3
5
.
6


1
.
6
5
~
N
M
_
0
0
6
8
7
5
P
i
m
-
2
o
n
c
o
g
e
n
e
(
P
I
M
2
)
3
4
.
2


1
.
2
9
~
N
M
_
0
0
1
0
0
1
8
5
2
P
i
m
-
3
o
n
c
o
g
e
n
e
(
P
I
M
3
)
3
5
.
8

5
.
7
9
~
N
M
_
0
0
3
6
6
8
M
i
t
o
g
e
n
-
a
c
t
i
v
a
t
e
d
p
r
o
t
e
i
n
k
i
n
a
s
e
-
a
c
t
i
v
a
t
e
d
p
r
o
t
e
i
n
k
i
n
a
s
e
5
(
M
A
P
K
A
P
K
5
)
5
4
.
2


2
.
7
7
~
N
M
_
0
2
5
1
9
5
T
r
i
b
b
l
e
s
h
o
m
o
l
o
g
1
(
D
r
o
s
o
p
h
i
l
a
)
(
T
R
I
B
1
)
4
1


0
.
8
3
!
N
M
_
0
0
4
9
7
2
J
a
n
u
s
k
i
n
a
s
e
2
(
J
A
K
2
)
1
3
0

1
1
.
5
1
~
N
M
_
0
0
2
0
3
7
F
Y
N
o
n
c
o
g
e
n
e
r
e
l
a
t
e
d
t
o
S
R
C
,
F
G
R
,
Y
E
S
(
F
Y
N
)
6
0
.
7


0
.
9
6
"
N
M
_
0
0
2
1
1
0
H
e
m
o
p
o
i
e
t
i
c
c
e
l
l
k
i
n
a
s
e
(
H
C
K
)
5
9
.
6

1
.
2
1
~
N
M
_
0
0
5
3
5
6
L
y
m
p
h
o
c
y
t
e
-
s
p
e
c
i
f
i
c
p
r
o
t
e
i
n
t
y
r
o
s
i
n
e
k
i
n
a
s
e
(
L
C
K
)
5
8

0
.
4
1
!
N
M
_
0
0
2
0
1
1
F
i
b
r
o
b
l
a
s
t
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
4
(
F
G
F
R
4
)
8
7
.
9

*
/
N
M
_
0
0
2
0
1
9
F
m
s
-
r
e
l
a
t
e
d
t
y
r
o
s
i
n
e
k
i
n
a
s
e
1
(
F
L
T
1
)
1
5
0
.
7

0
N
M
_
0
0
5
1
6
3
v
-
a
k
t
m
u
r
i
n
e
t
h
y
m
o
m
a
v
i
r
a
l
o
n
c
o
g
e
n
e
h
o
m
o
l
o
g
1
(
A
K
T
1
)
5
5
.
6


0
.
1
0
!
N
M
_
0
0
3
1
6
1
R
i
b
o
s
o
m
a
l
p
r
o
t
e
i
n
S
6
k
i
n
a
s
e
,
7
0
k
D
a
,
p
o
l
y
p
e
p
t
i
d
e
1
(
S
6
K
)
5
9
.
1

1
1
.
0
1
~
N
M
_
0
0
5
6
2
7
S
e
r
u
m
/
g
l
u
c
o
c
o
r
t
i
c
o
i
d
r
e
g
u
l
a
t
e
d
k
i
n
a
s
e
1
(
S
G
K
1
)
4
8
.
9


3
.
7
6
~
N
M
_
0
0
5
3
0
8
G
p
r
o
t
e
i
n
-
c
o
u
p
l
e
d
r
e
c
e
p
t
o
r
k
i
n
a
s
e
5
(
G
P
R
K
5
)
6
7
.
7


1
.
1
7
~
N
M
_
0
0
4
3
3
3
v
-
r
a
f
m
u
r
i
n
e
s
a
r
c
o
m
a
v
i
r
a
l
o
n
c
o
g
e
n
e
h
o
m
o
l
o
g
B
1
(
B
R
A
F
1
)
8
4
.
4

0
N
M
_
0
0
2
8
8
0
v
-
r
a
f
-
1
m
u
r
i
n
e
l
e
u
k
e
m
i
a
v
i
r
a
l
o
n
c
o
g
e
n
e
h
o
m
o
l
o
g
1
(
c
-
R
a
f
)
7
3


1
,
4
7
~
N
M
_
0
0
2
5
7
6
p
2
1
p
r
o
t
e
i
n
(
C
d
c
4
2
/
R
a
c
)
-
a
c
t
i
v
a
t
e
d
k
i
n
a
s
e
1
(
P
A
K
1
)
6
0
.
6

*
/
N
M
_
0
0
2
5
7
7
p
2
1
p
r
o
t
e
i
n
(
C
d
c
4
2
/
R
a
c
)
-
a
c
t
i
v
a
t
e
d
k
i
n
a
s
e
2
(
P
A
K
2
)
5
8
/
N
M
_
0
0
2
7
5
5
M
i
t
o
g
e
n
-
a
c
t
i
v
a
t
e
d
p
r
o
t
e
i
n
k
i
n
a
s
e
k
i
n
a
s
e
1
(
M
K
K
1
)
4
3
.
4

1
.
2
6
~
N
M
_
0
0
4
0
7
3
P
o
l
o
-
l
i
k
e
k
i
n
a
s
e
3
(
D
r
o
s
o
p
h
i
l
a
)
(
P
L
K
3
)
7
1
.
6


0
N
M
_
0
0
5
0
3
0
P
o
l
o
-
l
i
k
e
k
i
n
a
s
e
1
(
D
r
o
s
o
p
h
i
l
a
)
(
P
L
K
1
)
6
8
.
2


5
0
~
N
M
_
0
0
2
7
4
5
M
i
t
o
g
e
n
-
a
c
t
i
v
a
t
e
d
p
r
o
t
e
i
n
k
i
n
a
s
e
1
(
M
A
P
K
1
)
4
1
.
4

0
.
3
8
!
N
M
_
0
0
1
3
1
5
M
i
t
o
g
e
n
-
a
c
t
i
v
a
t
e
d
p
r
o
t
e
i
n
k
i
n
a
s
e
1
4
(
M
A
P
K
1
4
)
4
1
.
6

1
.
5
2
~
N
M
_
0
0
2
7
5
0
M
i
t
o
g
e
n
-
a
c
t
i
v
a
t
e
d
p
r
o
t
e
i
n
k
i
n
a
s
e
8
(
M
A
P
K
8
)
4
8
.
3

0
.
8
0
!
N
M
_
0
0
2
0
9
3
G
l
y
c
o
g
e
n
s
y
n
t
h
a
s
e
k
i
n
a
s
e
3
b
e
t
a
(
G
S
K
3
B
)
4
6
.
7

1
.
3
1
~
N
M
_
0
0
2
7
5
3
M
i
t
o
g
e
n
-
a
c
t
i
v
a
t
e
d
p
r
o
t
e
i
n
k
i
n
a
s
e
1
0
(
M
A
P
K
1
0
)
5
2
.
5

1
.
1
1
~
N
M
_
0
0
1
2
9
2
C
D
C
-
l
i
k
e
k
i
n
a
s
e
3
(
C
L
K
3
)
,
t
r
a
n
s
c
r
i
p
t
v
a
r
i
a
n
t
p
h
c
l
k
3
/
1
5
2
1
6
.
8

0
N
M
_
0
0
0
9
0
6
N
a
t
r
i
u
r
e
t
i
c
p
e
p
t
i
d
e
r
e
c
e
p
t
o
r
A
/
g
u
a
n
y
l
a
t
e
c
y
c
l
a
s
e
A
(
a
t
r
i
o
n
a
t
r
i
u
r
e
t
i
c
p
e
p
t
i
d
e
r
e
c
e
p
t
o
r
A
)
(
N
P
R
1
)
1
1
9


0
.
9
5
"
N
M
_
0
0
1
8
9
2
C
a
s
e
i
n
k
i
n
a
s
e
1
,
a
l
p
h
a
1
(
C
K
1
)
3
7
.
2

3
.
8
9
~
R
N
A
p
o
l
y
m
e
r
a
s
e
a
n
d
r
i
b
o
s
o
m
a
l
p
r
o
t
e
i
n
s
N
M
_
0
0
5
7
6
0
C
C
A
A
T
/
e
n
h
a
n
c
e
r
b
i
n
d
i
n
g
p
r
o
t
e
i
n
z
e
t
a
(
C
E
B
P
Z
)
1
2
0
.
9


*
/
N
M
_
0
1
5
6
5
8
N
u
c
l
e
o
l
a
r
c
o
m
p
l
e
x
a
s
s
o
c
i
a
t
e
d
2
h
o
m
o
l
o
g
(
S
.
c
e
r
e
v
i
s
i
a
e
)
(
N
O
C
2
L
)
8
5

1
.
3
4
~
N
M
_
0
2
2
4
5
1
N
u
c
l
e
o
l
a
r
c
o
m
p
l
e
x
a
s
s
o
c
i
a
t
e
d
3
h
o
m
o
l
o
g
(
S
.
c
e
r
e
v
i
s
i
a
e
)
(
N
O
C
3
L
)
9
2
.
5

*
/
N
M
_
0
2
4
0
7
8
N
u
c
l
e
o
l
a
r
c
o
m
p
l
e
x
a
s
s
o
c
i
a
t
e
d
4
h
o
m
o
l
o
g
(
S
.
c
e
r
e
v
i
s
i
a
e
)
(
N
O
C
4
L
)
5
8
.
5


0
.
7
6
!
N
M
_
0
0
3
7
0
3
N
O
P
1
4
n
u
c
l
e
o
l
a
r
p
r
o
t
e
i
n
h
o
m
o
l
o
g
(
y
e
a
s
t
)
(
N
O
P
1
4
)
9
7
.
7


0
N
M
_
0
1
4
9
7
6
P
r
o
g
r
a
m
m
e
d
c
e
l
l
d
e
a
t
h
1
1
(
P
D
C
D
1
1
)
2
0
8
.
7

1
.
9
1
~
N
M
_
0
0
6
3
3
1
E
M
G
1
n
u
c
l
e
o
l
a
r
p
r
o
t
e
i
n
h
o
m
o
l
o
g
(
S
.
c
e
r
e
v
i
s
i
a
e
)
(
E
M
G
1
)
2
6
.
7

1
.
2
7
~
Maertens et al. PROTEIN SCIENCE VOL 19:1312—1326 1315T
a
b
l
e
I
.
(
C
o
n
t
i
n
u
e
d
)
R
e
f
_
s
e
q
.
N
a
m
e
P
r
o
t
e
i
n
s
i
z
e
(
k
D
a
)
W
i
l
d
-
t
y
p
e
c
o
n
s
t
r
u
c
t
c
o
r
r
e
c
t
a
n
d
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
O
p
t
i
m
i
z
e
d
c
o
n
s
t
r
u
c
t
a
v
a
i
l
a
b
l
e
u
p
o
n
d
e
n
o
v
o
s
y
n
t
h
e
s
i
s
r
a
t
i
o
t
o
t
a
l
e
x
p
r
e
s
s
i
o
n
(
o
p
t
/
w
t
)
N
M
_
0
1
4
2
3
3
U
p
s
t
r
e
a
m
b
i
n
d
i
n
g
t
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
,
R
N
A
p
o
l
y
m
e
r
a
s
e
I
(
U
B
F
)
8
9
.
4

*
/
N
M
_
1
3
9
0
7
1
S
W
I
/
S
N
F
r
e
l
a
t
e
d
,
m
a
t
r
i
x
a
s
s
o
c
i
a
t
e
d
,
a
c
t
i
n
d
e
p
e
n
d
e
n
t
r
e
g
u
l
a
t
o
r
o
f
c
h
r
o
m
a
t
i
n
,
s
u
b
f
a
m
i
l
y
d
,
m
e
m
b
e
r
1
(
S
M
A
R
C
D
1
)
5
4
.
9

1
.
2
2
~
C
y
t
o
k
i
n
e
s
N
M
_
0
0
0
7
5
8
C
o
l
o
n
y
s
t
i
m
u
l
a
t
i
n
g
f
a
c
t
o
r
2
(
g
r
a
n
u
l
o
c
y
t
e
-
m
a
c
r
o
p
h
a
g
e
)
(
C
S
F
2
)
1
4
.
4


1
.
7
2
~
N
M
_
0
0
0
5
8
5
I
n
t
e
r
l
e
u
k
i
n
1
5
(
I
L
-
1
5
)
1
4
.
9


2
.
2
6
~
N
M
_
0
0
1
0
0
1
4
3
7
C
h
e
m
o
k
i
n
e
(
C
-
C
m
o
t
i
f
)
l
i
g
a
n
d
3
-
l
i
k
e
3
(
C
C
L
3
L
3
)
7
.
8

0
.
8
1
!
N
M
_
0
0
9
8
5
5
C
D
8
0
a
n
t
i
g
e
n
(
C
d
8
0
)
3
0
.
5

1
0
~
N
M
_
0
0
0
5
8
6
I
n
t
e
r
l
e
u
k
i
n
2
(
I
L
-
2
)
1
4
.
6


0
.
8
9
!
N
M
_
0
0
0
5
8
9
I
n
t
e
r
l
e
u
k
i
n
4
(
I
L
-
4
)
1
4
.
9

1
.
4
0
~
N
M
_
0
0
0
6
0
0
I
n
t
e
r
l
e
u
k
i
n
6
(
i
n
t
e
r
f
e
r
o
n
,
b
e
t
a
2
)
(
I
L
-
6
)
2
1


1
.
1
0
~
N
M
_
0
0
2
1
8
7
,
N
M
_
0
0
0
8
8
2
I
n
t
e
r
l
e
u
k
i
n
1
2
A
a
n
d
1
2
B
(
I
L
-
1
2
A
a
n
d
I
L
-
1
2
B
)
6
5

0
.
1
!
A
Y
8
9
0
6
8
9
,
N
M
_
0
0
0
6
1
9
,
N
P
_
0
0
0
6
1
0
S
y
n
t
h
e
t
i
c
c
o
n
s
t
r
u
c
t
H
o
m
o
s
a
p
i
e
n
s
c
l
o
n
e
F
L
H
0
3
1
1
9
8
.
0
1
L
i
n
t
e
r
f
e
r
o
n
g
a
m
m
a
(
I
F
N
G
)
1
6
.
8

0
.
5
3
!
N
M
_
0
0
6
8
5
0
I
n
t
e
r
l
e
u
k
i
n
2
4
(
I
L
-
2
4
)
1
8
.
2

2
.
7
1
~
N
M
_
0
0
0
8
8
0
I
n
t
e
r
l
e
u
k
i
n
7
(
I
L
-
7
)
1
7
.
4


2
~
N
M
_
0
0
0
5
7
2
I
n
t
e
r
l
e
u
k
i
n
1
0
(
I
L
-
1
0
)
1
8
.
6


1
.
0
0
"
N
M
_
0
2
4
0
1
3
I
n
t
e
r
f
e
r
o
n
,
a
l
p
h
a
1
(
I
F
N
-
a
)
1
9
.
2

5
~
N
M
_
0
0
0
5
9
4
T
u
m
o
r
n
e
c
r
o
s
i
s
f
a
c
t
o
r
(
T
N
F
-
a
)
1
7
.
4

1
.
5
6
~
N
M
_
0
0
2
9
8
5
C
h
e
m
o
k
i
n
e
(
C
-
C
m
o
t
i
f
)
l
i
g
a
n
d
5
(
C
C
L
5
)
7
.
5

2
.
7
2
~
T
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
s
N
M
_
0
2
1
9
7
5
v
-
r
e
l
r
e
t
i
c
u
l
o
e
n
d
o
t
h
e
l
i
o
s
i
s
v
i
r
a
l
o
n
c
o
g
e
n
e
h
o
m
o
l
o
g
A
(
a
v
i
a
n
)
(
R
E
L
A
)
6
0
.
2

2
~
N
M
_
0
2
0
5
2
9
N
u
c
l
e
a
r
f
a
c
t
o
r
o
f
k
a
p
p
a
l
i
g
h
t
p
o
l
y
p
e
p
t
i
d
e
g
e
n
e
e
n
h
a
n
c
e
r
i
n
B
-
c
e
l
l
s
i
n
h
i
b
i
t
o
r
,
a
l
p
h
a
(
N
F
j
B
I
A
)
3
5
.
6


1
.
1
1
~
N
M
_
0
0
1
4
2
9
E
1
A
b
i
n
d
i
n
g
p
r
o
t
e
i
n
p
3
0
0
(
E
P
3
0
0
)
2
6
4
.
1

0
N
M
_
0
0
2
2
2
8
J
u
n
o
n
c
o
g
e
n
e
(
A
P
1
)
3
5
.
7


2
.
6
3
~
N
M
_
0
0
2
0
4
9
G
A
T
A
b
i
n
d
i
n
g
p
r
o
t
e
i
n
1
(
g
l
o
b
i
n
t
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
1
)
(
G
A
T
A
1
)
4
2
.
7

0
.
9
1
!
N
M
_
0
1
5
8
5
9
G
e
n
e
r
a
l
t
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
I
I
A
,
1
,
1
9
/
3
7
k
D
a
(
T
F
I
I
A
)
4
1
.
5


5
0
~
N
M
_
0
0
0
5
4
6
T
u
m
o
r
p
r
o
t
e
i
n
p
5
3
(
p
5
3
)
4
3
.
7

0
.
5
1
!
N
M
_
0
0
3
4
0
3
Y
Y
1
t
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
(
Y
Y
1
)
4
4
.
7


2
.
5
7
~
N
M
_
0
0
1
5
1
4
G
e
n
e
r
a
l
t
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
I
I
B
(
T
F
I
I
B
)
3
4
.
8

0
.
8
3
!
N
M
_
0
0
4
3
7
9
c
A
M
P
r
e
s
p
o
n
s
i
v
e
e
l
e
m
e
n
t
b
i
n
d
i
n
g
p
r
o
t
e
i
n
1
(
C
R
E
B
1
)
3
6
.
7

1
.
3
0
~
N
M
_
0
1
6
2
6
9
L
y
m
p
h
o
i
d
e
n
h
a
n
c
e
r
-
b
i
n
d
i
n
g
f
a
c
t
o
r
1
(
L
E
F
1
)
4
4
.
2

0
N
M
_
0
1
8
9
5
2
H
o
m
e
o
b
o
x
B
6
(
H
O
X
B
6
)
2
5
.
4

1
.
1
7
~
N
M
_
0
0
5
9
0
1
S
M
A
D
f
a
m
i
l
y
m
e
m
b
e
r
2
(
S
M
A
D
2
)
5
2
.
3


0
.
8
5
!
N
M
_
0
0
5
2
3
8
v
-
e
t
s
e
r
y
t
h
r
o
b
l
a
s
t
o
s
i
s
v
i
r
u
s
E
2
6
o
n
c
o
g
e
n
e
h
o
m
o
l
o
g
1
(
a
v
i
a
n
)
(
E
T
S
-
1
)
5
0

0
.
8
6
!
N
M
_
0
1
4
5
9
6
z
i
n
c
r
i
b
b
o
n
d
o
m
a
i
n
c
o
n
t
a
i
n
i
n
g
1
(
Z
N
R
D
1
)
1
3
.
9

1
.
7
0
~
M
e
m
b
r
a
n
e
p
r
o
t
e
i
n
s
N
M
_
0
0
0
6
3
3
B
-
c
e
l
l
C
L
L
/
l
y
m
p
h
o
m
a
2
(
B
c
l
-
2
)
2
6
.
3

1
.
1
6
~
N
M
_
0
0
1
0
0
5
8
6
2
v
-
e
r
b
-
b
2
e
r
y
t
h
r
o
b
l
a
s
t
i
c
l
e
u
k
e
m
i
a
v
i
r
a
l
o
n
c
o
g
e
n
e
h
o
m
o
l
o
g
2
,
n
e
u
r
o
/
g
l
i
o
b
l
a
s
t
o
m
a
d
e
r
i
v
e
d
o
n
c
o
g
e
n
e
h
o
m
o
l
o
g
(
a
v
i
a
n
)
(
H
E
R
-
2
)
1
3
7
.
9

0
1316 PROTEINSCIENCE.ORG Human Gene Optimization for Expression in E. coliT
a
b
l
e
I
.
(
C
o
n
t
i
n
u
e
d
)
R
e
f
_
s
e
q
.
N
a
m
e
P
r
o
t
e
i
n
s
i
z
e
(
k
D
a
)
W
i
l
d
-
t
y
p
e
c
o
n
s
t
r
u
c
t
c
o
r
r
e
c
t
a
n
d
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
O
p
t
i
m
i
z
e
d
c
o
n
s
t
r
u
c
t
a
v
a
i
l
a
b
l
e
u
p
o
n
d
e
n
o
v
o
s
y
n
t
h
e
s
i
s
r
a
t
i
o
t
o
t
a
l
e
x
p
r
e
s
s
i
o
n
(
o
p
t
/
w
t
)
N
M
_
0
0
3
0
4
2
S
o
l
u
t
e
c
a
r
r
i
e
r
f
a
m
i
l
y
6
(
n
e
u
r
o
t
r
a
n
s
m
i
t
t
e
r
t
r
a
n
s
p
o
r
t
e
r
,
G
A
B
A
)
,
m
e
m
b
e
r
1
(
S
L
C
6
A
1
)
6
7


1
.
1
8
~
N
M
_
0
0
1
0
4
5
S
o
l
u
t
e
c
a
r
r
i
e
r
f
a
m
i
l
y
6
(
n
e
u
r
o
t
r
a
n
s
m
i
t
t
e
r
t
r
a
n
s
p
o
r
t
e
r
,
s
e
r
o
t
o
n
i
n
)
,
m
e
m
b
e
r
4
(
S
L
C
6
A
4
)
7
0
.
3

1
.
9
2
~
N
M
_
0
1
4
2
2
9
S
o
l
u
t
e
c
a
r
r
i
e
r
f
a
m
i
l
y
6
(
n
e
u
r
o
t
r
a
n
s
m
i
t
t
e
r
t
r
a
n
s
p
o
r
t
e
r
,
G
A
B
A
)
,
m
e
m
b
e
r
1
1
(
S
L
C
6
A
1
1
)
7
0
.
6

0
.
4
6
!
N
M
_
0
1
6
6
1
5
S
o
l
u
t
e
c
a
r
r
i
e
r
f
a
m
i
l
y
6
(
n
e
u
r
o
t
r
a
n
s
m
i
t
t
e
r
t
r
a
n
s
p
o
r
t
e
r
,
G
A
B
A
)
,
m
e
m
b
e
r
1
3
(
S
L
C
6
A
1
3
)
6
3
.
7


1
.
6
0
~
N
M
_
0
2
4
0
0
6
V
i
t
a
m
i
n
K
e
p
o
x
i
d
e
r
e
d
u
c
t
a
s
e
c
o
m
p
l
e
x
,
s
u
b
u
n
i
t
1
(
V
K
O
R
C
1
)
1
8
.
2

0
N
M
_
0
0
3
2
6
4
T
o
l
l
-
l
i
k
e
r
e
c
e
p
t
o
r
2
(
T
L
R
2
)
8
9
.
8

2
~
N
M
_
0
3
0
9
5
6
T
o
l
l
-
l
i
k
e
r
e
c
e
p
t
o
r
1
0
(
T
L
R
1
0
)
9
4


9
.
8
3
~
N
M
_
0
1
6
5
6
2
T
o
l
l
-
l
i
k
e
r
e
c
e
p
t
o
r
7
(
T
L
R
7
)
1
2
0
.
9

1
.
5
~
N
M
_
0
1
2
1
4
0
S
o
l
u
t
e
c
a
r
r
i
e
r
f
a
m
i
l
y
2
5
(
m
i
t
o
c
h
o
n
d
r
i
a
l
c
a
r
r
i
e
r
;
d
i
c
a
r
b
o
x
y
l
a
t
e
t
r
a
n
s
p
o
r
t
e
r
)
,
m
e
m
b
e
r
1
0
(
S
L
C
2
5
A
1
0
)
3
1
.
2

1
.
2
8
~
N
M
_
0
1
4
4
3
7
S
o
l
u
t
e
c
a
r
r
i
e
r
f
a
m
i
l
y
3
9
(
z
i
n
c
t
r
a
n
s
p
o
r
t
e
r
)
,
m
e
m
b
e
r
1
(
S
L
C
3
9
A
1
)
3
4
.
2


0
N
M
_
0
0
0
4
4
7
P
r
e
s
e
n
i
l
i
n
2
(
A
l
z
h
e
i
m
e
r
d
i
s
e
a
s
e
4
)
(
P
S
E
N
1
)
5
2
.
6

0
.
7
1
!
N
M
_
0
0
0
2
2
0
P
o
t
a
s
s
i
u
m
i
n
w
a
r
d
l
y
-
r
e
c
t
i
f
y
i
n
g
c
h
a
n
n
e
l
,
s
u
b
f
a
m
i
l
y
J
,
m
e
m
b
e
r
1
(
K
C
N
J
1
)
4
4
.
7

0
N
M
_
0
2
1
6
2
5
T
r
a
n
s
i
e
n
t
r
e
c
e
p
t
o
r
p
o
t
e
n
t
i
a
l
c
a
t
i
o
n
c
h
a
n
n
e
l
,
s
u
b
f
a
m
i
l
y
V
,
m
e
m
b
e
r
4
(
T
R
P
V
4
)
9
8
.
2

1
0
~
N
M
_
0
0
1
6
5
1
A
q
u
a
p
o
r
i
n
5
(
A
Q
P
5
)
2
8
.
3


0
N
M
_
0
0
5
2
2
8
E
p
i
d
e
r
m
a
l
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
(
e
r
y
t
h
r
o
b
l
a
s
t
i
c
l
e
u
k
e
m
i
a
v
i
r
a
l
(
v
-
e
r
b
-
b
)
o
n
c
o
g
e
n
e
h
o
m
o
l
o
g
,
a
v
i
a
n
)
(
E
G
F
R
)
1
3
4
.
2

0
N
M
_
0
0
1
7
5
3
C
a
v
e
o
l
i
n
1
,
c
a
v
e
o
l
a
e
p
r
o
t
e
i
n
(
C
A
V
1
)
2
0
.
4


1
0
.
9
5
~
N
M
_
0
0
0
5
9
3
T
r
a
n
s
p
o
r
t
e
r
1
,
A
T
P
-
b
i
n
d
i
n
g
c
a
s
s
e
t
t
e
,
s
u
b
-
f
a
m
i
l
y
B
(
M
D
R
/
T
A
P
)
(
T
A
P
1
)
8
0
.
9


0
N
M
_
0
0
0
5
4
4
T
r
a
n
s
p
o
r
t
e
r
2
,
A
T
P
-
b
i
n
d
i
n
g
c
a
s
s
e
t
t
e
,
s
u
b
-
f
a
m
i
l
y
B
(
M
D
R
/
T
A
P
)
(
T
A
P
2
)
7
5
.
6

0
N
M
_
0
0
5
5
6
1
L
y
s
o
s
o
m
a
l
-
a
s
s
o
c
i
a
t
e
d
m
e
m
b
r
a
n
e
p
r
o
t
e
i
n
1
(
L
A
M
P
1
)
4
4
.
7


0
N
M
_
0
0
2
2
9
4
L
y
s
o
s
o
m
a
l
-
a
s
s
o
c
i
a
t
e
d
m
e
m
b
r
a
n
e
p
r
o
t
e
i
n
2
(
L
A
M
P
2
)
4
4
.
9

0
N
M
_
0
1
4
3
9
8
L
y
s
o
s
o
m
a
l
-
a
s
s
o
c
i
a
t
e
d
m
e
m
b
r
a
n
e
p
r
o
t
e
i
n
3
(
L
A
M
P
3
)
4
4
.
3

0
N
M
_
0
0
0
0
8
6
C
e
r
o
i
d
-
l
i
p
o
f
u
s
c
i
n
o
s
i
s
,
n
e
u
r
o
n
a
l
3
(
C
L
N
3
)
4
7
.
6

0
.
3
1
!
N
M
_
0
1
4
3
1
9
L
E
M
d
o
m
a
i
n
c
o
n
t
a
i
n
i
n
g
3
(
L
E
M
D
3
)
9
9
.
9

0
N
M
_
0
0
0
9
1
4
O
p
i
o
i
d
r
e
c
e
p
t
o
r
,
m
u
1
(
O
P
R
M
1
)
4
4
.
7

1
.
4
9
~
N
M
_
0
2
3
9
2
1
T
a
s
t
e
r
e
c
e
p
t
o
r
,
t
y
p
e
2
,
m
e
m
b
e
r
1
0
(
T
A
S
2
R
1
0
)
3
5
.
3

0
N
M
_
0
0
2
5
0
7
N
e
r
v
e
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
(
N
G
F
R
)
4
5
.
1

0
‘
‘
O
t
h
e
r
’
’
p
r
o
t
e
i
n
s
N
M
_
0
0
4
5
2
3
K
i
n
e
s
i
n
f
a
m
i
l
y
m
e
m
b
e
r
1
1
(
K
I
F
1
1
)
1
1
9
.
1

2
.
3
3
~
N
M
_
0
0
1
0
1
2
2
7
1
B
a
c
u
l
o
v
i
r
a
l
I
A
P
r
e
p
e
a
t
-
c
o
n
t
a
i
n
i
n
g
5
(
B
I
R
C
5
)
1
6
.
4

0
.
5
9
!
N
M
_
0
0
1
7
8
6
C
e
l
l
d
i
v
i
s
i
o
n
c
y
c
l
e
2
,
G
1
t
o
S
a
n
d
G
2
t
o
M
(
C
D
C
2
)
3
4

3
.
4
7
~
G
e
n
e
s
a
r
e
s
u
b
d
i
v
i
d
e
d
i
n
p
r
o
t
e
i
n
f
a
m
i
l
i
e
s
t
h
e
y
e
n
c
o
d
e
f
o
r
(
k
i
n
a
s
e
s
,
R
N
A
p
o
l
y
m
e
r
a
s
e
a
n
d
r
i
b
o
s
o
m
a
l
p
r
o
t
e
i
n
s
,
c
y
t
o
k
i
n
e
s
,
t
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
s
,
m
e
m
b
r
a
n
e
p
r
o
t
e
i
n
s
a
n
d
t
h
r
e
e
‘
‘
o
t
h
e
r
p
r
o
-
t
e
i
n
s
’
’
)
.
C
o
l
u
m
n
s
a
r
e
(
l
e
f
t
t
o
r
i
g
h
t
)
:
R
e
f
_
s
e
q
.
:
G
e
n
e
B
a
n
k
a
c
c
e
s
s
i
o
n
n
u
m
b
e
r
;
N
a
m
e
:
g
e
n
e
s
y
m
b
o
l
a
n
d
c
o
m
p
l
e
t
e
g
e
n
e
n
a
m
e
;
p
r
o
t
e
i
n
s
i
z
e
:
s
i
z
e
o
f
f
u
l
l
-
l
e
n
g
t
h
p
r
o
t
e
i
n
;
w
i
l
d
-
t
y
p
e
c
o
n
s
t
r
u
c
t
c
o
r
-
r
e
c
t
a
n
d
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
:
r
e
f
e
r
s
t
o
R
Z
P
D
(
G
e
r
m
a
n
y
)
o
r
G
e
n
e
s
e
r
v
i
c
e
(
U
K
)
(
b
a
s
e
d
o
n
b
e
g
i
n
n
i
n
g
o
f
2
0
0
7
)
;
O
p
t
i
m
i
z
e
d
c
o
n
s
t
r
u
c
t
a
v
a
i
l
a
b
l
e
u
p
o
n
d
e
n
o
v
a
s
y
n
t
h
e
s
i
s
:
a
b
i
l
i
t
y
t
o
s
y
n
t
h
e
s
i
z
e
c
D
N
A
(

*
:
w
i
l
d
-
t
y
p
e
c
o
n
s
t
r
u
c
t
f
a
i
l
e
d
t
o
b
e
s
y
n
t
h
e
s
i
z
e
d
)
;
r
a
t
i
o
t
o
t
a
l
e
x
p
r
e
s
s
i
o
n
(
o
p
t
/
w
t
)
:
a
b
s
o
l
u
t
e
f
l
u
o
r
e
s
c
e
n
c
e
v
a
l
u
e
m
e
a
s
u
r
e
d
f
o
r
e
x
p
r
e
s
s
i
o
n
o
f
o
p
t
i
m
i
z
e
d
c
o
n
s
t
r
u
c
t
d
i
v
i
d
e
d
b
y
f
l
u
o
r
e
s
c
e
n
c
e
v
a
l
u
e
m
e
a
s
u
r
e
d
f
o
r
e
x
p
r
e
s
s
i
o
n
o
f
w
i
l
d
t
y
p
e
c
o
n
s
t
r
u
c
t
s
(
a
v
e
r
a
g
e
o
f
t
r
i
p
l
i
c
a
t
e
s
,
r
e
s
p
e
c
t
i
v
e
l
y
)
;
u
p
r
i
g
h
t
a
r
r
o
w
h
e
a
d
(
~
)
:
e
x
p
r
e
s
s
i
o
n
w
t
<
o
p
t
;
h
o
r
i
z
o
n
t
a
l
a
r
r
o
w
h
e
a
d
(
"
)
:
e
x
p
r
e
s
-
s
i
o
n
w
t
¼
o
p
t
(
þ
/
-
5
%
)
;
a
r
r
o
w
h
e
a
d
d
o
w
n
w
a
r
d
(
!
)
:
e
x
p
r
e
s
s
i
o
n
w
t
>
o
p
t
;
(
0
)
n
o
e
x
p
r
e
s
s
i
o
n
,
(
/
)
n
o
a
n
a
l
y
s
i
s
p
o
s
s
i
b
l
e
d
u
e
t
o
l
a
c
k
o
f
w
i
l
d
t
y
p
e
c
o
n
s
t
r
u
c
t
;
C
y
t
o
k
i
n
e
s
a
r
e
d
e
p
r
i
v
e
d
o
f
t
h
e
i
r
s
i
g
-
n
a
l
s
e
q
u
e
n
c
e
s
.
E
x
c
e
p
t
C
D
8
0
a
n
t
i
g
e
n
(
N
M
_
0
0
9
8
5
5
,
m
o
u
s
e
)
,
a
l
l
s
e
q
u
e
n
c
e
s
a
r
e
o
f
h
u
m
a
n
o
r
i
g
i
n
.
Maertens et al. PROTEIN SCIENCE VOL 19:1312—1326 1317versus 80%, 86.6% versus 73%, 50% versus 39.3% of
proteins expressed, respectively; Supporting Infor-
mation Figure 4(A)]. Overall, production levels of
70% of the expressible genes were higher upon opti-
mization (Table II). Optimized genes coding for cyto-
kines, membrane and ribosomal proteins performed
better than the overall average [78.6%, 78.6% and
80% of the genes, respectively, Supporting Informa-
tion Fig. 4(A)]. Histograms for absolute expression
rates are shown in Supporting Information Figure
4(C–G) for each protein. Although constructs which
failed in DNA synthesis belonged to the set of fifty
Figure 1. Workflow of multi-gene study: 100 wt and sequence-optimized genes were cloned or synthesized into a pQE-T7 E.
coli expression vector. PT7: T7 promoter; lac O: lac operator; RBS: ribosome-binding site; ATG: start codon; 6xHis: N-
terminal hexahistidine tag; wt/optimized: cloning cassette to receive the gene coding sequence; Amb: amber stop codon;
Stop: translational stop; ori: origin of replication; lacI: Lac repressor gene; Kanamycin: kanamycin resistance gene. The N-
terminal 6xHis tag is exoproteolytically cleavable using the TAGzyme system. Every QIAgene E. coli contains a universal stop
point for the TAGzyme protease.
18 His tag sequences can be deleted by NdeI restriction for generation of a construct for
expression of an untagged protein. The amber stop codon (UAG, Amb) can be used to incorporate a label making use of the
amber suppression principle.
19 Each wt and optimized construct was expressed in E.coli cells in vivo. The total cell lysate
was labeled with the dye Chromeo P503 which only becomes fluorescent upon binding to an amino group of a protein.
Lysates were separated on a SDS gel and scanned using an Ettan DIGE
TM Fluorescent Scanner. Signals were quantified
using the ImageQuant
TM TL software. The factor (3.76) displays the ratio of protein expression using optimized (opt) and wild
type (wt) sequences. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
1318 PROTEINSCIENCE.ORG Human Gene Optimization for Expression in E. colilarger constructs [47-264 kDa, Supporting Informa-
tion Fig. 4(B)], this mostly occurs with wt sequences (6
wt and 1 sequence-optimized construct). The probabil-
ity to benefit from sequence optimization in terms of
enhanced expression results is slightly reduced by
12% in the set of the larger constructs [Supporting In-
formation Fig. 4(B)]. Nevertheless, an important fea-
ture of optimization and de novo gene synthesis is
sequence availability and reliability which will allow
future investigation of any large protein in the first
place.
Purification and protein solubility
Results for IMAC purification via His tag under
native and/or denaturing conditions are shown for
24 candidates of our multi-gene study (Table III).
The amount which can be expressed and purified is
protein dependent and ranged between 1.2 to 80 mg/l
culture volume measured in elution fractions of
expressions using sequence-optimized genes. In the
cases where we purified and quantified the protein
expressed using both wt and sequence-optimized
constructs a yield ratio was calculated and can be
compared to the expression ratio from Table I
achieved by fluorescent quantification of total
lysates. In 16 out of 17 cases the ratios of expression
and purification match well, only in case of MAPK8
we analyzed an inverted tendency (Table III). This
strong correlation shows that enhanced expression
levels using sequence-optimized constructs can not
Table II. Summary of In Vivo Expression Results of wt and Sequence-Optimized Genes
Cases of
opt >wt (%)
Cases of
opt ¼ wt (%)
Cases of
opt <wt (%)
No
expression
(%)
Ratio total
expression
(opt s wt, mean)
Ratio total
expression
(opt/wt, median)
All genes (n ¼ 94) 54.3 3.2 20.2 22.3 / /
Expressible genes (n ¼ 73) 70.0 4.1 25.9 / 3.50 1.29
In total, 73 out of 94 constructs could be expressed in vivo.
Table III. Amount of Protein After IMAC Purification Using 25 wt and Sequence-Optimized Genes for Expression
in E. coli
Name
Protein yield (mg/L) Purification mode Yield ratio after purification Ratio total expression
Wild-type
gene
Optimized
gene
Native (N)/
denat. (D)
opt/wt
(elution fractions)
opt/wt
(lysate)
Pim-1 10.5 19.4 N 1.85 1.65 ~
Pim-2 n.d. 10 N 1.29 ~
MAPKAPK5 14.9 80 N 5.37 2.77 ~
TRIB1 11.3 6.3 N 0.56 0.83 !
FYN n.d. 6 N 0.96 "
MAPK1 24.3 11.5 N 0.47 0.38 !
MAPK14 n.d. 43 N 1.52 ~
MAPK8 33.8 42.2 N 1.25 0.80 !
EMG1 30 31.5 N 1.05 1.27 ~
IFN gamma 76 22 N 0.29 0.53 !
IFN alpha 0 13.3 N 5.00 ~
TNF alpha n.d. 68 N 1.56 ~
NFKB1a 34 34.8 N 1.02 1.11 ~
YY1 n.d. 24 N 2.57 ~
TFIIB 19.1 4 N 0.21 0.83 !
Kif11 2 3.5 N 1.75 2.33 ~
CDC2 8.2 14 N 1.71 3.47 ~
Caveolin 1 0 1.2 N 10.95~
CSF2 8.5 23.8 D 2.80 1.72 ~
IL-4 25.5 34.8 D 1.36 1.40 ~
IL-6 19.6 21.2 D 1.08 1.10 ~
IL-7 0 16.2 D 2.00 ~
IL-10 6 5.8 D 0.97 1.00 "
IFN alpha 0 25.5 D 5.00 ~
TNF alpha 25.5 38.6 D 1.51 1.56 ~
CCL5 n.d. 63 D 2.72 ~
TFIIB 25.9 19 D 0.73 0.83 !
Columns are (left to right): Name: gene symbol; wt gene: amount of protein quantified after expression and purification
using the wt coding sequence; optimized gene: amount of protein quantified after expression and purification using the
optimized coding sequence; n.d.: not determined; native/denat.: purification performed under native or denaturing condi-
tions; yield ratio (opt/wt): factor calculated from protein yield in purification elution fractions; ratio total expression (opt/
wt): factor calculated from expression level in crude lysates (see Table I).
Maertens et al. PROTEIN SCIENCE VOL 19:1312—1326 1319only be detected in crude lysates but also results in
enhanced amounts of protein amenable for chro-
matographic recovery. Purification of membrane pro-
teins was only done for Caveolin 1 in our multi-gene
study since a screen to determine the most suitable
detergent would have had to be performed for each
member of this class of proteins to enable successful
purification. In case of Caveolin 1, only the use of an
optimized sequence results in significant protein
expression (Fig. 2, Table III). IFN alpha is another
example where only sequence optimization leads to
purification of a noteworthy amount of protein (Fig.
2, Table III). In cases where full-length proteins are
difficult to express or purify (e.g., JAK2) or show
degradation products (e.g., TLR2), the optimized cod-
ing sequences have also proven useful to efficiently
express single domains of the protein (Supporting
Information Fig. 5).
Multi-parameter gene optimization versus host
supplementation with rare tRNAs
The impact of tRNA availability to compensate for
rare codons in wt cDNAs was determined and com-
pared to the effects achievable by a multi-parameter
optimization. We determined the expression level of
wt cDNAs encoding human genes in E. coli strains,
which co-express certain rare tRNAs (Rosetta2,
BL21-CodonPlus), and of their sequence-optimized
counterparts in E. coli BL21(DE3) without any addi-
tional tRNAs. First, we analyzed the distribution of
rare codons in silico and grouped the 100 human
genes listed in Table I into three categories, where,
on average, either every 6th, 12th or 22nd amino
acid is encoded by a rare codon. The impact of co-
expression of rare tRNAs should decrease within
this series. The comparison was performed with two
to three members of each of the groups (seven
Figure 2. Optimized sequences increase yield of soluble protein in in vivo E. coli expression system. The expression in E. coli
BL21(DE3) and Ni-NTA purification via His tag under native conditions of four wild type (WT) and optimized (OPT) sequences
and optimized CAV1 is shown (wt CAV1 cannot be detected). Samples were analyzed on a SDS gel and stained with
Coomassie Brilliant blue. Arrows indicate the protein of interest, arrowheads show lysozyme; elution fractions (E) were
quantified with a Bradford assay and 3 lg protein was separated in case of sequence-optimized expression in comparison to
the same volume of wt protein fraction. TL: total lysate, CL: cleared lysate; 2.5 lL of each fraction were separated R:
resolubilized membrane fraction; BT: break through; W: wash. Note that some protein in the cleared lysates is insoluble and
purification of the soluble protein results in enrichment in the elution fraction. Marker: Page ruler prestained protein Ladder
(Fermentas); for more information on the genes and proteins see Table I. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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the expression level of all candidates was highest
when we expressed the sequence-optimized construct
in BL21(DE3) cells without any additional tRNAs
[Fig. 3(A,B)]. Whereas gene optimization reliably led
to substantial protein expression even in a conven-
tional BL21(DE3) strain in all cases tested, the rare
tRNA supplemented Rosetta2 (CSF-2) and the BL21
CodonPlus strain (PLK1, CSF-2, and Caveolin 1) in
some cases failed to promote production of the pro-
tein of interest. These data suggest that more factors
than simply the availability of rare tRNAs contrib-
ute to efficient expression of human genes in E. coli,
which are accounted for in the multi-parameter gene
optimization software.
Molecular mechanisms underlying the level of
human gene expression in E. coli
To characterize the molecular mechanisms underly-
ing the observed modulation of human protein
expression in E. coli, we compared the mRNA tran-
script level during recombinant protein expression
from wt and sequence-optimized constructs, respec-
tively. For two different scenarios the correlation
between mRNA level and efficiency of protein
expression was analyzed: (i) the optimized construct
shows higher expression level than the wt construct
(e.g., CK1, ratio opt/wt 3.89), (ii) the optimized con-
struct shows lower expression level than the wt con-
struct (e.g., LCK, ratio opt/wt 0.41). The transcript
level was monitored at four different time points
with regard to IPTG induction by relative quantifi-
cation with real-time PCR. Since the nucleotide
sequences of optimized and wt DNA differ up to
30%, we first examined the amplification efficiencies
of different primer sets using at least 6-log template
dilution series to ensure the comparability of the
detected mRNA expression levels (Supporting Infor-
mation Fig. 6 and Table II). We then monitored
mRNA levels during recombinant protein expression
of both wt and sequence-optimized genes in two in-
dependent expression experiments and determined
the increase in mRNA abundance relative to the
transcript level prior IPTG induction. In the case of
sequence-optimized CK1, IPTG induction caused a
1400-fold change of the mRNA level after 4 hours
while transcript levels of wt CK1 did not increase
more than 38-fold in response to induction. This is
in agreement with a higher and more rapid protein
expression for the optimized construct [Fig. 4(A)].
Analysis of the mRNA levels of LCK showed a 500-
fold increase of mRNA transcripts for the wt gene in
response to 1 hour of IPTG induction whereas the
mRNA level for the sequence-optimized gene was
only elevated about 130-fold, which could be also
observed at the protein expression level [Fig. 4(B)].
In these two cases tested, mRNA and protein expres-
sion levels correlated suggesting that an increase of
mRNA is required to achieve an increase on the pro-
tein level. However, the ratio values show that the
resulting effect on the mRNA level is not necessarily
proportional to the effect on the protein level.
Discussion
This multi-gene study evaluates the influence of
sequence optimization on the level of protein expres-
sion of human genes in E. coli. Unlike previous
reports describing individual expression studies,
11–16
Figure 3. Enhanced codon usage is only one aspect of gene optimization. (A) Human wt genes coding for PLK1, SMARCD1,
CSF2, AP-1, YY1, CCL5, and CAV1 were expressed in Rosetta2 (white) and BL21CodonPlusRIPL (grey) E. coli strains, both
supplemented with rare tRNAs. Wt and sequence-optimized genes coding for the same proteins were expressed in E. coli
BL21(DE3) (black). (B) Lysates were labeled and quantified using the fluorescent dye Chromeo P503, separated on an SDS
gel and analyzed with an Ettan DIGE scanner. Proteins bands were evaluated using the ImageQuant TL software. Every
expression was done in triplicates. WT: wild type sequences; OPT: optimized sequences; C: control (mock transformation).
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classes which were optimized using a standardized
multi-parameter algorithm and the expression was
analyzed side by side to their wt counterpart. We
expressed full-length proteins without systematically
screening deletions, domain boundaries, tag positions
or expression conditions. Such methods can increase
the amount of expressed soluble protein
22 and may be
required when producing a single protein domain in
high amounts
23 as shown here by high-level expres-
sion of TLR2 and Jak2 subdomains (Supporting In-
formation Fig. 5). Besides optimization, de novo gene
synthesis provides for the accurate gene whereas
only one third of the wt genes obtained from commer-
cial sources showed the correct and complete DNA
sequence compared to its EntrezGene entry. Due to
freedom of sequence design, 99 of 100 sequence-opti-
mized genes were successfully synthesized whereas 6
wt genes failed. We developed an expression vector
which contains a cleavable N-terminal His-tag and a
tightly regulated T7 promoter. A fluorescence-based
method for reliable protein quantification using the
fluorescent dye Chromeo P503 was applied to quan-
tify in vivo protein expression with a fluorescent
imaging system. Membrane and a few weakly
expressed proteins were detected by Western blotting
using a fluorescence-labeled primary antibody
24
directed against the His tag.
In our opinion, the use of rationally designed
synthetic genes has several advantages over wt
cDNAs: (i) 99% in contrast to 34% of the desired con-
structs were readily available with a reliable, proven
sequence, (ii) the chance to achieve expression of a
protein was elevated from 69 to 78% in our study
using sequence-optimized constructs, and (iii) the
level of expression was enhanced 3.5-fold on aver-
age. We observed a success rate of 70% using
sequence-optimized genes (enhanced expression com-
pared to wt genes). This observation matches closely
with results already seen for the expression of 30
human sequence-optimized short-chain dehydrogen-
ase/reductase genes.
11
Cells grew to higher cell densities when express-
ing sequence-optimized genes, probably due to a
more efficient translation of heterologous transcripts
which might lead to accelerated cell growth in gen-
eral. As postulated by Kudla et al., a mRNA tran-
scribed from an optimized gene might sequester
fewer ribosomes resulting in smoother translation
which could lead to an increase of the total cellular
protein synthesis and thus cell growth.
25
In cases where optimized genes expressed lower
than wt genes, OD values of the bacterial cultures
also lacked behind. Negative influence of the accu-
mulating protein within the bacterial cell, especially
when using autoinduction medium, might be one
Figure 4. mRNA level correlates with amount of recombinant protein. Expressions of CK1 (A), LCK (B) were analyzed at 4
different time points after IPTG induction at mRNA and protein level. 6   10
8 cells were harvested, total RNA was isolated
and used for relative quantification by two-step real-time PCR. Real-time PCR measurements were done in triplicate with
samples from two independent experiments. The fold changes in mRNA expression relative to the mRNA level at T0 are
plotted against the time after induction. Representative Western blots show the expression levels of the corresponding
proteins. Total cell lysates from an identical number of cells at the different time points post induction were subjected to
SDS-PAGE and subsequent Western blotting using Penta-His HRP Conjugate.
1322 PROTEINSCIENCE.ORG Human Gene Optimization for Expression in E. coliexplanation for the observation of a higher expres-
sion level measured for 19 wt genes (wt > opt). In
three out of ten cases tested (kinase FYN and tran-
scription factors NFjBIA and GATA1), expression
level analysis after a shorter induction period
showed an inverse result (opt > wt; data not shown).
In addition to in vivo expression, all constructs were
analyzed in an E. coli cell-free expression system
(Supporting Information Table 4). Similar to in vivo,
cell-free expression levels of wt genes were higher in
13 out of these 19 cases. With 5 out of 15 genes in
vivo and 6 out of 15 in the cell-free expression system
this finding was most pronounced within the group of
transcription factors. This might be explained with
disturbing effects of these foreign DNA-binding pro-
teins to the transcriptional regulation of the host cell
machinery. Even though it is commonly believed that
proteins toxic to the living cell can generally be
expressed in the corresponding cell-free lysate
26 it is
obvious that cellular functions such as transcription
are also required for in vitro transcription/translation
systems. Whether or not DNA binding or other effects
are responsible for the failure to express certain pro-
teins like transcription factors will have to be eluci-
dated by more selective studies. Assuming that ho-
mologous expression of such proteins does not or not
as severely disturb the physiology of the host, the tox-
icity hypothesis is indirectly supported by the fact
that in a similar study conducted in eukaryotic cells
expression of all transcription factors could be
increased by gene optimization (Stephan Fath, Ralf
Wagner et al., manuscript in preparation).
We observed a good correlation between cell-free
and in vivo expression in E. coli as it has been
reported in other studies
27,28 and confirm that cell-
free expression is a convenient screening tool for
small-scale protein expression.
We did not check for solubility of all proteins
expressed using sequence-optimized constructs, but
34.2% of those tested could be purified under native
conditions and an additional 30% worked under
denaturing conditions. This degree of solubility is
slightly higher than described in other studies.
29
The exact yield was quantified for 24 proteins and
varied between 1.2 and 80 mg/L bacterial culture.
The expression ratios determined in crude cell-
lysates and the yield ratios calculated from amounts
of purified protein show a good correlation. There-
fore, sequence-optimization does not only result in
enhanced expression levels in crude cell-lysates but
also in elevated protein amounts that can be puri-
fied. Beyond that, protein expressed from sequence-
optimized constructs does not change its solubility
compared to protein derived from wt sequences.
It has been postulated that although heterol-
ogous expression can be improved by altering the
codon preference, the effect can generally be
achieved by introducing rare codon tRNAs into the
host cell.
11 Our results clearly show that an adapted
codon bias is only one parameter which contributes
to an enhanced expression level using sequence-opti-
mized genes. In all cases analyzed here and in a
study reported previously,
4 the expression level of wt
genes in bacterial strains supplemented with rare
tRNAs was exceeded significantly by using
sequence-optimized counterparts in nonsupple-
mented strains. This might be in accordance with
the finding that simply choosing the codons most
frequently used by an expression host will not
ensure protein expression. Instead, the use of codons
served by tRNAs during translation which are most
efficiently recharged seems to be important in situa-
tions of amino acid starvation.
30 Recently, it was
reported that the use RosettaDE3 strains leads to
improved purity of purified protein rather than to a
great enhancement of protein expression levels.
31
The mRNA stability at the 50terminus has an
influence on the expression level of heterologously
expressed genes in E. coli. A lower amount of free
energy corresponds to weaker hairpins in the 50
region of mRNAs and therefore enhances translation
initiation efficiency.
25,32 One of our algorithm param-
eters aims at avoiding hairpin forming inverted
repeats in the 50 region but we did not observe a cor-
relation between lower DG values and enhanced
expression levels (Supporting Information Table 3).
However, all of our constructs contained a 24 nucleo-
tide His tag in the 50 region which is known to ele-
vate recombinant protein expression.
27,33,34 We
believe that this leader sequence attenuates mRNA
secondary structure formation and allows efficient
initiation of translation. Therefore, at least in case of
N-terminally tagged proteins other factors discussed
in this study seem to play a more important role
than a low amount of free energy in the 50 region.
Our data show that the mRNA amount clearly cor-
relates with protein expression levels in case of LCK
and CK1. Factors like a prolonged half-life or a reduced
sensitivity for RNA nucleases might be explanations
for elevated mRNA levels. At this point it is probably
fair to state that, compared to the situation in mamma-
lian expression systems, the impact of mRNA optimiza-
tion in E. coli is not as well understood. Certainly how-
ever, effects during translation elongation can also
have an influence on protein expression since the ratio
of maximum mRNA levels of optimized to wt for CK1
is 36.8 whereas the protein ratio is only 3.9, and ratios
for LCK are 0.26 (mRNA) and 0.41 (protein). These
data show that despite the high success rate of increas-
ing yields of full-length human proteins details of the
molecular mechanisms underlying translational control
remain to be elucidated. The fact that 20% of the gene
sequences calculated by our algorithm resulted in lower
expression compared to the wt cDNA suggests a poten-
tial for further improvement in gene design for heterol-
ogous protein expression.
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conclusion that an improved codon usage is not the
only parameter which has to be considered when
using an expression system like E. coli for heterol-
ogous protein production. In fact, an optimization
strategy has to provide a balance of (i) an adapted
codon choice, (ii) a balanced GC-content, (iii) avoid-
ance of sequence repeats and other DNA motifs, and
(iv) the avoidance of mRNA secondary structures
especially at the translation initiation region, all of
which is accounted for in our algorithm. In our view,
the gene redesign concept can be regarded as the
method of choice for expression of recombinant pro-
teins, since it not only guarantees the availability of
an expression construct of correct sequence but also
significantly increases success, that is expression
rate. This applies to heterologous expression of
human genes in E. coli and may also hold true for
homologous expression of human genes in human
(HEK293) as well as in insect cells (Stephan Fath,
Ralf Wagner et al., manuscript in preparation). As
the improved success rate applies to high-level pro-
duction of full-length proteins the concept promises
to facilitate investigation of multi-protein complexes,
an important future goal in biochemistry.
Material and Methods
Plasmids and bacterial strains
The pQE-T7 vector (Qiagen) contains a T7 promotor,
a lac operator sequence, a T7 termination signal, a
lacI gene for cis mediated repression and a gene con-
ferring resistance to kanamycin. A coding sequence
cloned into this vector expresses a N-terminal 6x His
tag sequence (MKHHHHHHMKQ) which is exopro-
teolytically removable with the TAGzyme system.
18
An amber stop codon for co-translational label incor-
poration by amber suppression is inserted at the C-
terminus.
19 All cloning and plasmid propagation
steps were carried out using E. coli strain DH10B
(Invitrogen) and EZ Competent Cells (Qiagen).
Expression trials were performed using the E. coli
strains BL21(DE3) (Lucigen), BL21-CodonPlus (DE3)-
RIPL (Stratagene) and Rosetta2 (DE3) (Novagen).
Construct design and cloning
Standard human gene sequences were retrieved
from the NCBI GeneEntrez database and the coding
region was optimized using the GeneOptimizer
V R
expert software system (Geneart AG) as described
elsewhere.
17 Briefly, optimization parameters
include codon usage, DNA motifs such as ribosomal
entry sites, GC content and avoidance of (inverted)
repeats. All optimized genes were then assembled by
synthetic oligonucleotides (de novo gene synthesis),
cloned and sequence verified. Very large genes were
first divided into subgenetic fragments, which were
then assembled from oligonucleotides using PCR,
cloned and sequence verified. Next, these subfrag-
ments were fused by PCR and then cloned and
sequence verified. The wt (‘‘native’’) versions of the
same genes were obtained from the RZPD, Germany
or Geneservice, UK, if available (based on the begin-
ning of 2007). All cDNA clones from clone selections
were sequence verified after receipt. Only those
clones encoding for the very same amino acid
sequence as specified by their respective GeneEntrez
database entry were used as templates for further
subcloning steps. Those wt genes, which either could
not be obtained from clone selections or showed non-
silent mutations resulting in a different amino acid
sequence than specified by GeneEntrez, were synthe-
sized de novo as described above. All optimized and
wt coding sequences (Supporting Information Table
1) were subcloned into the pQE-T7 expression vector
and the correctness of the resulting constructs was
verified by DNA sequencing. For efficient protein
expression in E. coli signal sequences were removed
from wt and optimized constructs, respectively, based
on information in the NCBI database. Optimized
human genes for expression of His-tagged proteins in
E. coli or eukaryotic expression systems as used in
this study are marketed as QIAgenes by QIAGEN.
Protein expression
Wt and optimized expression constructs were trans-
formed into E. coli BL21(DE3) and, if indicated,
additionally into rare tRNA-supplemented E. coli
strains BL21CodonPlus(DE3)-RIPL and Roset-
ta2(DE3). Three independent colonies were inocu-
lated into 5 mL Luria-Bertani (LB) broth containing
kanamycin (50 lg/mL), with addition of chloram-
phenicol (34 lg/mL) for the Rosetta2(DE3) and
BL21CodonPlus(DE3)-RIPL strains, and grown over-
night in a 24-deep-well block at 30 C with shaking
at 160 rpm. Overnight cultures were then diluted to
a final OD600 nm of 0.1 in 5 mL of freshly prepared
autoinduction medium
20 with suitable antibiotics
and incubated for 24 h at 30 C in a 24-deep-well
block with shaking at 160 rpm before cells were har-
vested by centrifugation.
Quantification of expression
For the quantification of in vivo expressed proteins,
cell pellets were resuspended in lysis buffer B (100
mM NaH2PO4,1 0m M Tris-Cl, 7 M Urea, pH8.0)
containing 10 U/mL of Benzonase (Merck) and prote-
ase inhibitor cocktail (Complete EDTA-Free, Roche)
and lysed by shaking at 600 rpm for 1 h at room
temperature. The crude lysates were labeled with
Chromeo P503 (Active Motif) as described previ-
ously.
21 Briefly, proteins were denatured in 2x sam-
ple buffer (62.5 mM Tris, pH 8.5, 20% (v/v) glycerol,
4% (w/v) SDS and 3% (w/v) DTT) for 5 min at 95 C
and ChromeoP503 dye was added to the samples at
a final concentration of 125 lM. Labeling reactions
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subjected to SDS-PAGE. Membrane proteins were
analyzed by Western blotting using a fluorescent pri-
mary antibody. Crude lysates were separated by
SDS-PAGE and transferred onto nitrocellulose mem-
branes. Membranes were blocked with 5% bovine se-
rum albumin (BSA), incubated with Penta-His Alexa
Fluor 647 Conjugate (Qiagen) diluted 1:500 in 3%
BSA and washed three times with TBS. Recombinant
protein-specific bands in SDS-gels and on Western
blots were detected using the Ettan DIGE Imager
(GE Healthcare). Corresponding wt and optimized
constructs were analyzed in triplicates on the same
gel or Western blot, respectively, and scanned with
decreasing intensity until no saturation was visible.
The protein bands were quantified using the Image-
Quant TL software (GE Healthcare). Lysate from E.
coli cells transformed with the empty expression con-
struct served as negative controls for analysis.
Protein purification
For purification of His-tagged proteins under native
conditions, lysis was performed by resuspending
cells in buffer NPI-10 (50 mM NaH2PO4, 300 mM
NaCl, 10 mM imidazole, pH 8.0) containing 1 mg/mL
lysozyme (Roche), 10 U/mL Benzonase and protein-
ase inhibitor cocktail followed by an incubation for
30 min on ice. For purification under denaturing
conditions, the lysis buffer contained 8 M urea or 6
M Gu-HCl, respectively. Cleared lysates were
obtained through a centrifugation step (20 min,
13.000g, 4 C) and incubated with Ni-NTA Magnetic
Agarose Beads (Qiagen) for 1 h at 4 C. Beads were
separated using magnetic force and washed twice
with NPI-20 (50 mM NaH2PO4, 300 mM NaCl, 20
mM imidazole, pH 8.0). Protein was eluted twice
with NPI-500 (50 mM NaH2PO4, 300 mM NaCl, 500
mM imidazole, pH 8.0). Protein concentrations were
determined by Bradford protein assay (Bio-Rad) and
elution fractions analyzed by SDS-PAGE with subse-
quent Coomassie staining using Imperial Protein
Stain (Thermo Scientific).
Analysis of mRNA levels
Overnight cultures of cells freshly transformed with
either wt or optimized LCK or CK1 coding sequen-
ces, respectively, were diluted to an OD600 nm of 0.1
in 20 mL LB medium containing kanamycin (50 lg/
mL) and grown at 37 C in a shaking incubator. At
an OD600 nm of 0.8-1.0 cells were induced with 1mM
isopropyl-b-D-thiogalactopyranoside (IPTG). Samples
containing 6   10
8 cells were taken immediately
before the addition of IPTG and 0.5, 1 and 4 hours
after induction and were harvested directly into
RNAprotect Bacteria Reagent (Qiagen). Total RNA
was isolated using the RNeasy Protect Bacteria Mini
Kit (Qiagen) including an on-column DNAse diges-
tion step with the RNase-Free DNase Set (Qiagen)
according to the manufacture’s instructions. RNA
quantity and quality was assessed using the Nano-
Drop
V R ND-1000 UV-Vis Spectrophotometer (Nano-
Drop Technologies). Reverse Transcription of 1 lg
total RNA was performed with the QuantiTect
Reverse Transcription Kit (Qiagen) in accordance to
the manufacturer’s protocol. All oligonucleotides
were purchased from Sigma. The final primer set
selection was based on the efficiency of amplifica-
tion. All real-time PCR reactions were performed
with an Applied Biosystems 7700 Sequence Detec-
tion System using the QuantiTect SYBR Green PCR
Kit (Qiagen). For each sample, PCR was carried out
in triplicate in 25 ll reaction volumes containing
cDNA corresponding to 0.25–0.025 ng RNA. Amplifi-
cation conditions comprised an initial activation step
of 15 min at 95 C followed by 40 cycles of 94 C for
15 s, 55–56 C for 30 s and 72 C for 30 s.
To ensure comparability between data for the
same target obtained from different PCR runs, the
threshold value was manually set to the same value
for data analysis. For the calculation of the relative
changes in gene expression the Pfaffl method
35 was
applied taking the amplification efficiencies into
account. Briefly, delta Ct values were calculated by
subtracting the mean Ct of each sample from the
mean Ct of the control (samples taken immediately
before induction) and then the amount of target rel-
ative to the control was computed by E
DCt target. Val-
ues were obtained from measurements of two differ-
ent cDNAs generated in two independent expression
experiments.
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